Alcoholic Hepatitis Therapeutics Market Size, Share, Global Trends, Forecast to 2032

Alcoholic Hepatitis Therapeutics Market Insights

According to a report from Zion Market Research, the global Alcoholic Hepatitis Therapeutics Market was valued at USD 136.05 Million in 2023 and is projected to hit USD 767.74 Million by 2032, with a compound annual growth rate (CAGR) of 21.2% during the forecast period 2024-2032. This report explores market strengths, weakness, opportunities, and threats. It also provides valuable insights into the market's growth drivers, challenges, and the future prospects that may emerge in the Alcoholic Hepatitis Therapeutics Market industry over the next decade.

Request Free Sample

The report offers assessment and analysis of the alcoholic hepatitis therapeutics market on a global and regional level. The study offers a comprehensive assessment of the market competition, constraints, revenue estimates, opportunities, evolving trends, and industry-validated data. The report provides historical data from 2018 to 2022 along with a forecast from 2024 to 2032 based on revenue USD Million.

Request Free Sample

Alcoholic Hepatitis Therapeutics Market: Synopsis

Alcoholic hepatitis is severe hepatic inflammation related to morbidity & mortality and occurs in persons consuming large proportion of alcohol. In addition to this, it is a syndrome in patients that causes acute chronic liver failure. Apparently, alterations in gut microbiota, cytokine signaling & inflammation, mitochondrial dysfunction, oxidative stress, and abnormities in hepatic regeneration capacity are predicted to contribute towards alcoholic hepatitis pathology.

Furthermore, hospitalized alcoholic hepatitis patients result in massive healthcare expenditure and hence it is necessary for finding an effective treatment for this ailment. Additionally, alcoholic hepatitis can affect the gastrointestinal system, hematologic system, renal system, central nervous system, and cardiovascular system. It can injure hepatocyte and impair intestinal barrier activity. Symptoms of the alcoholic hepatitis include anorexia, fever, fatigue, weight loss, and right upper quadrant abdominal pain.

In addition to this, alcoholic hepatitis is a multisystem ailment that occurs due to intake of alcohol in huge quantities over an elongated period. Growth of the disease depends on ecological & genetic aspects. The key treatment for the disease includes abstinence from alcohol beverage consumption & supportive patient care. Moreover, corticosteroids are the most efficient medical treatment method but they can only improve the rate of survival in selective groups of patients for only a shorter period. 

Reportedly, men consuming over 100 gram of ethanol regularly for more than five years are at high risk of getting affected from alcoholic hepatitis. While in the case of women, ingesting a small proportion of ethanol in short term can cause alcoholic hepatitis. Some of other treatments for alcoholic hepatitis include nutritious food and use of medicines such as methadone, pentoxifylline, and N-acetyl cysteine. Additionally, behavioral therapy, baclofen, and rehabilitation are some of the other therapies that are utilized in treating alcoholic hepatitis.  Other emerging treatments include probiotics, antibiotics, zinc, melatonin, FXR agonist, mycophenolate, emricasan, anakinra, mitoq, metadoxine, interleukin-22, and erythropoietin.

Alcoholic Hepatitis Therapeutics Market: Growth Factors

The surge in intake of alcohol and a rise in alcoholic liver ailment will drive the growth of the alcoholic hepatitis therapeutics market. In addition to this, surging knowledge about the pathophysiology of alcoholic hepatitis along with the availability of substitute therapies will drive industry trends. For the record, nearly 56,809 hospital admissions with primary diagnosis of alcoholic hepatitis contributed nearly 0.71% of overall hospital admissions in the U.S. during 2007. Moreover, total hospitalization costs incurred on treating alcoholic hepatitis were more compared to costs incurred for treatment of acute cerebrovascular ailment, acute myocardial infarction, and acute pancreatitis. This, in turn, will drive growth of alcoholic hepatitis therapeutics market size.

Furthermore, a strong medicine pipeline is predicted to steer the expansion of the alcoholic hepatitis therapeutics market. In addition to this, rise in acceptance of new therapeutic medicines and increase in cases of liver transplantations in patients will further boost business trends.

Alcoholic Hepatitis Therapeutics Market: Report Scope

Alcoholic Hepatitis Therapeutics Market: Regional Landscape

North American Market To Record Exponential Growth During 2024 – 2032

Prominent market expansion in North America over forecast period can be attributed to robust healthcare sector and adoption of new drugs for treating alcoholic hepatitis. In addition to this, the huge occurrence of disease in the region will further contribute to alcoholic hepatitis therapeutics' market value in North America over the upcoming years. In addition to this, the presence of major drug producers for treating the disease in the sub-continent will steer regional market growth.

Alcoholic Hepatitis Therapeutics Market: Competitive Landscape

Some of the leading in the global market include

• Sanofi
• Gilead Sciences Inc.
• Immuron Limited
• Generon Pharmaceutical Technology Company Limited
• Intercept Pharmaceuticals Ltd.

The global Alcoholic Hepatitis Therapeutics Market is segmented as follows:

By Product Type

• Monoclonal Antibodies
• Corticosteroids
• Hemorheology agents
• Caspase protease inhibitor
• Anabolic steroids
• Sulfhydryl agents
• Hepatotropic Hormones

By Distribution Channel

• Hospital Pharmacies
• Retail  Pharmacies
• Online Pharmacies

By Region

• North America
  • The U.S.
  • Canada
• Europe
  • France
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of the Middle East & Africa